Axon Seminar In Vitro Diagnostics Wednesday 12 September 2012

Bringing an in vitro diagnostic product to the market is challenging and complex. Rules at the EU and national level are constantly changing, while regulatory policy is developing to get to grips with new products. A robust and scientifically supported regulatory and legal strategy is therefore key to successful market access.

Speakers and their presentations:

Sabine Ohse, Head Medical Devices Certification at BSI Group Regulatory strategy for in vitro diagnostics in the EU

Henk Vietor, CEO at Skyline Diagnostics Company experience with regulatory issues and how to deal with them

Erik Vollebregt, Partner at Axon Lawyers IVD Capita Exotica

Carine van den Brink, Partner at Axon Lawyers Promotion and sale of IVDs in EU


Navigate through our knowledgebase

Related articles

Article

This was not the Corrigendum you were looking for

So, we have had yet another couple of weeks with many things happening, so you may enjoy the two core slides from a recent presentation of mine at the NEN MDR conference…

Read more

Article

Regulatory pathways for clean meat in the EU and the US – differences & analogies

Now that the US regulatory framework is shaping up, the analogies and differences with the European regulatory framework for market access for clean meat becomes more and more clear. This blogpost reports these analogies and differences, based on the agreement that the FDA and USDA recently concluded on their cooperation in the field of clean […]

Article

Cannabis derived food products – what’s the current state of play?

Recently, CBD food products were qualified as Novel Foods requiring a market authorization. The lively trade in these products therefore currently seems to be at risk. However, not all cannabis derived products…

Read more